These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18412875)

  • 21. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod.
    Alarcon I; Carrera C; Alos L; Palou J; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Jul; 71(1):49-55. PubMed ID: 24725478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical imiquimod therapy for lentigo maligna.
    Mahoney MH; Joseph MG; Temple C
    Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periocular lentigo maligna treated with imiquimod.
    O'Neill J; Ayers D; Kenealy J
    J Dermatolog Treat; 2011 Apr; 22(2):109-12. PubMed ID: 20666668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
    Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
    Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lentigo maligna: review of salient characteristics and management.
    Kallini JR; Jain SK; Khachemoune A
    Am J Clin Dermatol; 2013 Dec; 14(6):473-80. PubMed ID: 24019181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.
    Erickson C; Miller SJ
    Int J Dermatol; 2010 May; 49(5):482-91. PubMed ID: 20534080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imiquimod use in the treatment of lentigo maligna.
    Junkins-Hopkins JM
    J Am Acad Dermatol; 2009 Nov; 61(5):865-7. PubMed ID: 19836644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lentigo maligna: current concepts in diagnosis and management.
    Walling HW
    G Ital Dermatol Venereol; 2009 Apr; 144(2):149-55. PubMed ID: 19357622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
    Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
    JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of lentigo maligna with topical imiquimod.
    Naylor MF; Crowson N; Kuwahara R; Teague K; Garcia C; Mackinnis C; Haque R; Odom C; Jankey C; Cornelison RL
    Br J Dermatol; 2003 Nov; 149 Suppl 66():66-70. PubMed ID: 14616356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amelanotic lentigo maligna managed with topical imiquimod.
    Lapresta A; García-Almagro D; Sejas AG
    J Dermatol; 2012 May; 39(5):503-5. PubMed ID: 21973079
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
    Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
    Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [How I treat ... lentigo maligna by topical imiquimod].
    Bourguignon R; Paquet P; Quatresooz P; Piérard GE
    Rev Med Liege; 2005 Sep; 60(9):691-4. PubMed ID: 16265961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases.
    de Troya-Martín M; Frieyro-Elicegui M; Fúnez Liébana R; Aguilar Bernier M; Fernández-Canedo NI; Blázquez Sánchez N
    Dermatol Surg; 2008 Nov; 34(11):1561-6. PubMed ID: 18798748
    [No Abstract]   [Full Text] [Related]  

  • 40. Remission of extensive lentigo maligna after treatment with imiquimod.
    Piazza CD; Sampaio SA
    An Bras Dermatol; 2009; 84(1):82-4. PubMed ID: 19377765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.